



## **ACTION REQUIRED**

### Fibrinogen Concentrate – Educational Resources and Supply

Customer Letter # 2020-14

---

2020-04-08

Dear Colleagues:

On March 31<sup>st</sup>, 2020, the National Emergency Blood Management Committee recommended hospitals use fibrinogen concentrate for the treatment of acquired hypofibrinogenemia to decrease demand on cryoprecipitate, reference Please see attached [Green Phase Advisory dated March 31, 2020](#). Canadian Blood Services would like to highlight two points about fibrinogen concentrate related to the availability of educational resources and supply of product.

Currently, Canadian Blood Services distributes the following two brands of fibrinogen concentrate:

- a. Fibryga® by Octapharma.
- b. RiaSTAP® by CSL Behring.

Both Octapharma and CSL Behring have developed several resources and services to assist hospitals in training their staff with the utilization of their products. For more information, please see the attached letters from the manufacturers outlining how to access training guides, educational materials, and other resources to support staff.

When initially introduced last year, Customer Letter [2019-23](#) noted that the confirmed supply of Fibryga® was estimated to only meet about 50% of total fibrinogen demand, and customers were asked to order Fibryga® to meet up to 50% of their demand. Canadian Blood Services appreciates your cooperation in this regard and is pleased to announce that 60% of fibrinogen demand can now be met with Fibryga®. **Our target brand distribution mix has been revised to 60% Fibryga® and 40% RiaSTAP®.**

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at [www.blood.ca](http://www.blood.ca) in the “Hospitals Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Sylvain Grenier,  
Director, Plasma Related Products Formulary Program